Malaria Diagnostics Market - By Product (Instruments, Kits & Reagents), Technology (Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic Tests [Conventional PCR & RT PCR]), End-use (Clinics, Hospitals, Diagnostic Centers)– Global Forecast (2024 – 2032)

Malaria Diagnostics Market Size

Malaria Diagnostics Market size was valued at around USD 819.1 million in 2023 and is estimated to grow at 5% CAGR from 2024 to 2032. Malaria diagnostics refer to the methods and techniques used to detect the presence of malaria parasites in a person's blood. These diagnostics are crucial for the prompt and accurate diagnosis of malaria, which is essential for effective treatment and disease control.
 

Malaria remains a significant global health concern, particularly in tropical and subtropical regions where it is endemic. In 2022, the World Health Organization (WHO) reported a staggering global burden of malaria, with an estimated 249 million cases and 608,000 deaths recorded across 85 countries. The WHO African region bore the brunt of this burden, accounting for a disproportionately high share. With 94% of malaria cases (equating to 233 million) and 95% (580,000) of malaria-related fatalities occurring within this region alone, the impact was particularly severe.
 

Alarmingly, children under the age of 5 bore the heaviest toll, representing approximately 80% of all malaria deaths within the African region. Thus, the enduring prevalence of malaria in these areas fuels a considerable need for diagnostic tools that can swiftly and accurately detect cases, thereby stimulating market growth.
 

Furthermore, awareness campaigns, educational programs, and public health initiatives have bolstered understanding of malaria transmission, prevention, and the crucial role of early diagnosis and treatment. By empowering communities with knowledge about malaria risk factors, symptoms, and available diagnostic options, these efforts drive demand for malaria diagnostics, as individuals are motivated to seek timely testing and treatment.
 

Malaria Diagnostics Market Trends

Point-of-care testing (POCT) which is estimated to reach USD 78.3 billion by 2032, plays a pivotal role in malaria diagnosis, especially in remote or resource-limited settings where access to centralized laboratory facilities is limited.
 

• Portable and easy-to-use POCT devices, such as rapid diagnostics and handheld microscopy tools, enable rapid detection of malaria infections within minutes, facilitating prompt treatment initiation and reducing the burden on healthcare systems.
   
• The scalability, affordability, and user-friendly nature of POCT devices make them indispensable tools for decentralized healthcare delivery in developing countries, propelling their adoption and uptake.
   
• Further, technological advancements have led to the development of more accurate, sensitive, and rapid diagnostic tests for malaria. These include molecular techniques such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and nucleic acid amplification testing, which offer high sensitivity and specificity.
   

Malaria Diagnostics Market Analysis

Based on product, the market is divided into instruments and kits & reagents. The kits & reagents segment is forecasted to reach USD 857.4 million by 2032, showcasing robust growth propelled by several key factors.
 

• Ongoing advancements in diagnostic technologies have led to the development of more accurate, rapid, and cost-effective diagnostic kits and reagents for malaria. These innovations enhance the efficiency of malaria diagnosis, leading to earlier detection and treatment initiation.
   
• Furthermore, despite concerted global efforts to combat malaria, the disease remains a significant public health challenge in many regions, particularly in sub-Saharan Africa and parts of Asia.
   
• The persistent burden of malaria underscores the critical need for accurate and accessible diagnostic solutions. Therefore, as malaria continues to pose a threat to global health, the demand for reliable diagnostic kits and reagents is expected to rise steadily.
   

Based on technology, the malaria diagnostics market is bifurcated into microscopy, rapid diagnostic tests, molecular diagnostic tests, and other technologies. The rapid diagnostic tests segment accounted for USD 432.3 million in 2023.
 

• The rapid diagnostic tests (RDTs) segment has emerged as a pivotal force in the malaria diagnostic market, boasting rapid results, ease of use, and point-of-care testing capabilities.
   
• With their ability to deliver prompt and reliable results, RDTs have become indispensable tools in regions with limited access to laboratory facilities, facilitating early detection and treatment of malaria infections. Their affordability and government support have further propelled their widespread adoption, particularly in resource-constrained settings.
   

Based on end-use, the malaria diagnostics market is bifurcated into clinics, hospitals, diagnostic centers, and other end-users. The clinics segment accounted for USD 343.9 million in 2023.
 

• Clinics serve as primary points of healthcare access, especially in malaria-endemic regions, making them pivotal for disease detection and treatment. Their utilization of point-of-care testing enables rapid and convenient diagnosis, facilitating prompt initiation of treatment and reducing transmission risk.
   
• Additionally, clinics actively engage in community outreach and public health campaigns, promoting awareness and encouraging testing. With integrated healthcare services and trained professionals, clinics offer comprehensive care, instilling confidence in patients and reinforcing the importance of timely diagnosis.
   

The malaria diagnostics market in the U.S. accounted for a significant revenue of USD 303.1 million in 2023, and this trajectory is set to continue upwards.
 

• The U.S. healthcare expenditure continues to rise, propelled by factors such as increasing population, aging demographics, and advancements in medical technology. With a greater focus on preventive healthcare and early disease detection, there's a growing demand for diagnostic tests, including those for malaria.
   

The malaria diagnostics market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany's position as a global hub for travel and commerce means that there is a continuous influx of travelers from malaria-endemic regions. Therefore, there is a heightened risk of imported malaria cases. This will necessitate robust diagnostic infrastructure to promptly identify and manage cases, further boosting the demand for malaria diagnostics.
   

Japan malaria diagnostics market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan's government has historically prioritized healthcare infrastructure and disease surveillance. Continued investments in healthcare infrastructure, research, and development will further bolster the market. Government initiatives aimed at raising awareness about malaria prevention, diagnosis, and treatment will also drive demand for diagnostic solutions.
   

The malaria diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The increasing population and healthcare expenditure in Saudi Arabia, coupled with growing interest in sophisticated diagnostic technologies for malaria and other infectious diseases, are expected to drive significant growth in the market in the country. This surge in interest indicates a recognition of the importance of early and accurate diagnosis in combating infectious diseases effectively.
   

Malaria Diagnostics Market Share

The malaria diagnostics sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Malaria Diagnostics Market Companies

Some of the eminent market participants operating in the malaria diagnostics industry include:

• Abbott Laboratories
• Access Bio
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Danaher corporation
• F. Hoffmann-La Roche Ltd.
• Nikon Corporation
• Premier Medical Corporation Private Limited
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
   

Malaria Diagnostics Industry News:

• In March 2024, Roche announced the approval of the cobas Malaria test by the U.S. Food and Drug Administration (FDA) for use on the cobas 6800/8800 systems. This approved test offers healthcare professionals an effective means to mitigate the risk of patient infection from transfused blood products. With its high sensitivity and specificity, the cobas Malaria test enables the identification and removal of infected blood units from the blood supply, bolstering safety measures. This regulatory milestone is expected to enhance the competitive position of Roche in the market.
   
• In August 2022, Bio-Rad acquired Curiosity Diagnostics, a developer of innovative technology solutions for the medical diagnostic and healthcare markets. Curiosity's PCRONE system was a pre-commercial platform technology for the rapid, automated detection of infections using highly multiplexed PCR assays. This acquisition extended Bio-Rad's reach beyond high-complexity labs into near-patient molecular diagnostics.
   

The malaria diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Kits & reagents

Market, Technology

• Microscopy
• Rapid diagnostic tests
• Molecular diagnostic tests
  • Conventional PCR
  • Real-time PCR
• Other technologies

Market, By End-use

• Clinics  
• Hospitals
• Diagnostic centers
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa